Drug Trial Radar · NCT06333964
A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children
Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
169
Actual
Start
Aug 29, 2023
Primary completion
Dec 5, 2024
Study completion Dec 5, 2024
Sponsor
- Lead sponsor
- Astrogen, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. Study purpose: To demonstrate the superiority of AST-001 compared to placebo in improving core symptoms of autism spectrum disorder (ASD) in children with ASD. 2. Background: ASD is a neurodevelopmental disorder characterized by deficits in social communication and social interaction as well as restricted, repetitive patterns of behavior, interests, or activities. There are no approved medicines to treat the core symptom of ASD. Although these drugs and other psychotropic medications are associated with side effects, the use of psychotropic drugs to treat associated psychiatric comorbidities is common. AST-001 is developed to treat the core symptom of ASD. 3. Design: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 clinical trial followed by an Open-Label Extension Treatment Period
Conditions
- Autism Spectrum Disorder
Interventions
AST-001Drug
AST-001, PO bid for 24weeks (dosage according to weight range)
Placebo of AST-001Drug
Placebo of AST-001, PO bid for 12 weeks + AST-001, PO bid for 12 weeks (dosage according to weight range)
Primary outcomes
What the sponsor says the trial is designed to measure.
- K-VABS-II (Korean-Vineland Adaptive Behavior Scale-II)Time frame: Baseline, 12week, 24week
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Chungnam National University Hospital
Daejeon, South Korea
Asan Medical Center
Seoul, South Korea
Hanyang University Seoul Hospital
Seoul, South Korea
Koera University Guro Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
Soon Chun Hyang University Hospital Cheonan
Cheonan, Chungcheongnam-do, South Korea
Hallym University Medical Center
Anyang-si, Gyeonggi-do, South Korea
Samsung Changwon Medical Center
Changwon, Gyeongsangnam-do, South Korea
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
Jeonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.